Neuropore Therapies, Inc. announced that it entered into a collaboration with BenevolentAI to evaluate molecular targets implicated in progressive degenerative diseases which were identified through artificial intelligence.
The molecular targets of interest are implicated in dysfunctions in proteostasis and can, therefore, be modulated to restore normal cellular protein clearance mechanisms. The collaboration aims to discover small molecule therapeutics for multiple targets.
Errol De Souza, President and CEO of Neuropore, stated,
“We are very excited to establish this collaboration with BenevolentAI. The application of artificial intelligence to the elaboration of novel approaches to medicine is one of the leading edges of science and is an approach that is bound to lead to new discoveries. Neuropore’s Autophagy Platform is a perfect testing ground for new hypotheses and discoveries. In addition to its drug discovery capabilities, Neuropore’s development and translational experience in degenerative disease make it a great fit for both companies.”
Anne Phelan, SVP BenevolentAI, said,
“The collaboration between Neuropore and BenevolentAI offers now a fantastic opportunity to accelerate the discovery of new medicines. Neuropore has built a world-leading platform for experimentally evaluating key processes within protein homeostasis, a critical biological mechanism in neurodegenerative diseases such as ALS. This system will allow the rapid and thorough evaluation of multiple novel targets, discovered using the BenevolentAI Platform, and enable us to validate new targets faster than ever.”